Tarperprumig

他扑米单抗

Report date: 2026/04/28 20:00:22

Base Information

Drug NameTarperprumig
Drug Alias NameALXN-1820
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionSerum albumin bindersProperdin inhibitors
TargetsSerum albuminProperdin
Therapy Area/IndicationsAnemia, Sickle CellAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAlexion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlexion Pharmaceuticals IncAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A